Last reviewed · How we verify
NCT05258617
Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery
trial testing LLLT Photobiomodulation in COVID-19 in 5 participants. Terminated before completion.
21 November 2022
Quick facts
| Lead sponsor | Ward Photonics LLC |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 5 |
| Start date | 24 February 2022 |
| Primary completion | 21 November 2022 |
| Estimated completion | 21 November 2022 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- LLLT Photobiomodulation
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
Sponsor
Ward Photonics LLC
Who can join
18 and older, any sex, with COVID-19 or Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An informational evaluation of COVID-19 patients who receive low-level laser therapy in addition to a normal regimen of treatment for symptoms associate with COVID-19. Results are compared to statistical observations published in literature from patients receiving standard care for COVID-19 symptoms without low-level laser therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05258617
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Ward Photonics LLC trials
Trials by the same sponsor.
- NCT04524715 — LLLT Treatment of Lung Inflammation in COVID-19 · NA · withdrawn
- NCT04525573 — Effects of a Red/Gold/IR LED Combination Light on Reduction of Fat · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05258617 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ward Photonics LLC
- Last refreshed: 28 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05258617.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing